Key facts
- GSK has licensed a cancer drug from Chinese biopharmaceutical company Hansoh Pharmaceutical.
- The deal is worth up to US$750 million.
- GSK gains rights to develop and commercialize the drug, HS-10163, in the US, Europe, and Japan.
British pharmaceutical giant GSK has entered into a licensing agreement with Chinese biopharmaceutical company Hansoh Pharmaceutical for a cancer drug. The deal, valued at up to US$750 million, grants GSK the rights to develop and commercialize the drug, identified as HS-10163, in key markets including the United States, Europe, and Japan.